Covishield produced more antibodies than Covaxin, finds preliminary study

The study, which is a preprint and has not been peer-reviewed, should not be used to guide clinical practice. However, it claimed that seropositivity rates to anti-spike antibodies were significantly higher in Covishield recipients

Asian News International June 07, 2021 15:13:59 IST
Covishield produced more antibodies than Covaxin, finds preliminary study

A health worker administers a covid-19 vaccine to a a man during a special vaccination drive held in the premises of a government school in Hyderabad, India, Sunday, May 30, 2021. (AP Photo/Mahesh Kumar A.)

New Delhi: Covishield vaccine produced more antibodies than Covaxin, according to the coronavirus Vaccine-induced Antibody Titre (COVAT) preliminary study involving healthcare workers (HCW) who have received both doses of either of the two vaccines.

Seropositivity rates to anti-spike antibodies were significantly higher in Covishield recipients compared to Covaxin after the first dose, the study claimed.

The study is a preprint and has not been peer-reviewed, so should not be used to guide clinical practice.

It said that both vaccines – Covishield and Covaxin – elicited a good response after two doses, but seropositivity rate and median anti-spike antibody were significantly higher in Covishield.

"Amongst the 552 HCW (325 Male, 227 Female), 456 and 96 received the first dose of Covishield and Covaxin respectively. Overall, 79.3 percent showed seropositivity after the first dose. Responder rate and median (IQR) rise in anti-spike antibody were significantly higher in Covishield vs. Covaxin recipient (86.8 vs. 43.8 percent; 61.5 vs. 6 AU/ml; both p<0.001)," the study said.

The study involved those healthcare workers who have been administered either of the two vaccines Covishield and Covaxin and are with or without past history of SARS-CoV-2 infection.

"This ongoing, Pan-India, Cross-sectional, coronavirus Vaccine-induced Antibody Titre (COVAT) study is being conducted amongst HCW, with or without past history of SARS-CoV-2 infection. SARS-CoV-2 anti-spike binding antibody is being assessed quantitatively at four-time points between 21 days or more after the first dose to 6 months after the second dose," the study said.

However, the conclusion of the study said that both the vaccines have shown elicited good immune response.

"While both vaccines elicited immune response, seropositivity rates to anti-spike antibody were significantly higher in Covishield recipient compared to Covaxin after the first dose. Ongoing COVAT study will further enlighten the immune response between two vaccines after the second dose," it said.

Updated Date:

also read

COVID-19 updates: PM cancels CBSE, ICSE Class 12 Board exams; daily cases lowest in 54 days
India

COVID-19 updates: PM cancels CBSE, ICSE Class 12 Board exams; daily cases lowest in 54 days

Addressing a press conference on COVID-19 among children, the NITI Aayog said that though the 2019 SARS coronavirus has not taken a serious shape among children till now, its impact can increase if there is a change in virus behaviour

Kerala, West Bengal report negative wastage of COVID-19 vaccines in May, Jharkhand has highest, says govt data
India

Kerala, West Bengal report negative wastage of COVID-19 vaccines in May, Jharkhand has highest, says govt data

Punjab, Delhi, Rajasthan, Uttar Pradesh, Gujarat, and Maharashtra reported 7.08%, 3.95%, 3.91%, 3.78% 3.63% and 3.59% respectively

COVID Updates: Daily cases decline by 78% decline since May peak; ICMR to start national sero survey
India

COVID Updates: Daily cases decline by 78% decline since May peak; ICMR to start national sero survey

Citing the sustained decline in daily coronavirus cases, the Centre said the COVID-19 situation in the country 'appears to be stabilising'